Multiple myeloma trials in China

In China 203 Also abroad 704

203 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Early phase 1Taking people
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Where
Tianjin
Age
18 years to 75 years
People
18
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07322159
No phaseEnrolling by invitation
Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
Where
Shanghai
People
40
Run by
RenJi Hospital
See details and how to joinNCT07833046
Phase 2Not yet taking people in China
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Where
Beijing
Age
18 years to 75 years
People
64
Run by
Excyte Biopharma Ltd
See details and how to joinNCT07695740
Phase 1Taking people
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Where
Kunming
Age
18 years and over
People
24
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07239323
Phase 2Taking people
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Beijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Xi'an
Age
18 years and over
People
510 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00
Phase 4Taking people
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Where
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
Age
18 years and over
People
295 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00
Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Beijing, Changchun, Changsha, Changzhou, Chaoyang District, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xiamen, Xi'an, Zhengzhou
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Nanning, Shanghai, Wenzhou, Wuhan, Xi'an
Age
18 years and over
People
400 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00
Phase 1Taking people
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
Where
Shanghai
Age
18 years and over
People
122
Run by
Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT07914556
Phase 1Not yet taking people in China
Universal CAR-T Cells Targeting Multiple Myeloma
Where
Shenzhen
Age
18 years to 80 years
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT06006741
Phase 1/2Not yet taking people in China
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Where
Shenzhen
Age
18 years to 80 years
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT06429150
Phase 1Not yet taking people in China
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Where
Shenzhen
Age
18 years to 80 years
People
10
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT06435910
Phase 3Not yet taking people in China
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Where
Tianjin
Age
18 years and over
People
320
Run by
Keymed Biosciences Co.Ltd
See details and how to joinNCT07910903
Phase 1/2Not yet taking people in China
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Where
Shenzhen
Age
18 years to 80 years
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03271632
Phase 3Taking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Beijing, Changsha, Chongqing, Deyang, Guangzhou, Hangzhou, Kunming, Linhai, Liuzhou, Luoyang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Ürümqi, Wenzhou, Wuhan, Wuxi, Xiamen, Xi'an, Zhengzhou
Age
18 years and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
Phase 1/2Taking people
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Where
Beijing, Changsha, Guangzhou, Shenyang
Age
18 years and over
People
226 worldwide
Run by
AstraZeneca
See details and how to joinNCT06106945 · EU 2023-508590-89-00
Phase 4Taking people
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
Where
Nanjing
Age
18 years to 70 years
People
200
Run by
Chen Lijuan
See details and how to joinNCT07907211
Phase 2Not yet taking people in China
QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
Where
Tianjin
Age
18 years and over
People
55
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07903636
Phase 3Taking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
Age
18 years and over
People
1,060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
Phase 2Taking people
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
Where
Tianjin
Age
18 years to 70 years
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07106684
Phase 2Taking people
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Where
Tianjin
Age
18 years to 70 years
People
30
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07106710
Phase 2Taking people
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Where
Tianjin
Age
18 years to 75 years
People
60
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07106736
Phase 1/2Taking people
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Where
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
Age
18 years and over
People
246 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00
Phase 2Not yet taking people in China
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Where
Tianjin
Age
18 years to 75 years
People
24
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07830485
Phase 3Taking people
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Beijing, Shanghai
Age
18 years to 130 years
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637